MISSISSAUGA, Ontario, Jan. 21, 2011 /PRNewswire/ —
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International,
Inc. (NYSE & TSX: VRX) announced today that the European
Medicines Agency’s Committee for Medicinal Products for Human Use
(CHMP) has issued a positive opinion, recommending marketing
authorisation for Trobalt™ (retigabine) as an
adjunctive (add-on) treatment of partial onset seizures (a form of
epilepsy where a seizure begins in a specific area in one side of
the brain), with or without secondary generalisation in adults aged
18 years and above with epilepsy.
Retigabine received a preliminary approval from the Swiss Agency
for Therapeutic Products, Swissmedic, in December 2010.
Retigabine, referred to as ezogabine in the US, is being jointly
developed by GSK and Valeant.
GlaxoSmithKline – one of the world’s leading
research-based pharmaceutical and healthcare companies – is
committed to improving the quality of human life by enabling people
to do more, feel better and live longer. For further
information please visit www.gsk.com.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:
VRX) – is a multinational specialty pharmaceutical company that
develops, manufactures and markets a broad range of pharmaceutical
products primarily in the areas of neurology, dermatology and
branded generics. More information about Valeant can be found
Enquiries:UK Media enquiries:
(020) 8047 5502Claire Brough
(020) 8047 5502Stephen Rea
(020) 8047 5502Alexandra Harrison
(020) 8047 5502US Media enquiries:
(919) 483 2839Mary Anne Rhyne
(919) 483 2839Kevin Colgan
(919) 483 2839Jennifer Armstrong
(919) 483 2839European Analyst/Investor enquiries: